Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Claris Ventures
Turin, Piedmont, Italyclarisventures.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Claris Ventures is a leading Italian venture capital firm focused on early-stage investments in high-potential biopharma startups. Through its funds—Claris Biotech I and II—it has financed 10+ biotech companies addressing major unmet needs in oncology, neurology, cardiometabolic disease and rare disorders. Four therapeutic programs from its first fund have already entered clinical development. Portfolio companies have collectively raised over €170 million and attracted interest from major pharmaceutical groups such as Sanofi, Bristol Myers Squibb and ONO Pharmaceutical
- Therapeutic areas
- OncologyRare DiseasesImmunologyCardiovascularNeurology
- Modalities
- Small moleculeMonoclonal antibodyGene therapy
- Industry
- Investors
02
Partnerships
Beyond the preview
Go deeper on Claris Ventures.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claris Ventures.